PMID- 30541695
OWN - NLM
STAT- MEDLINE
DCOM- 20190709
LR  - 20190709
IS  - 2468-0869 (Electronic)
IS  - 2468-0451 (Linking)
VI  - 24
IP  - 1
DP  - 2019 Feb
TI  - Pre-travel counseling for immunocompromised travelers: A 12-year single-center 
      retrospective review.
PG  - 13-22
LID - S2468-0451(18)30141-X [pii]
LID - 10.1016/j.idh.2018.09.083 [doi]
AB  - BACKGROUND: Immunocompromised travelers (ICTs) are medically complex and 
      challenging for travel medicine providers. Our study hypothesizes that ICTs have 
      high-risk travel itineraries and do not have adequate immunity against 
      vaccine-preventable infections. METHODS: This retrospective review of 321 ICTs 
      from 2004 to 2015 included patients with solid organ transplant (SOT, n = 134), 
      connective tissue disease (CTD, n = 121), inflammatory bowel disease (IBD, 
      n = 46), and human immunodeficiency virus (HIV, n = 20). Variables included 
      immunosuppressive medications, hepatitis A and B vaccination and serology, 
      gamma-globulin use, and antimalarial and antidiarrheal prophylaxis. Chi-square 
      analysis was used for categorical variables and Kruskal-Wallis for continuous 
      variables. RESULTS: Malaria-endemic regions accounted for 38.9% (125/321) of 
      travel destinations. High-risk activities were planned by 37.4% (120/321) of 
      travelers. A significant proportion of HIV patients [70.0% (14/20)] visited 
      friends and relatives, whereas other ICTs traveled for tourism. Hepatitis A and B 
      vaccination rates were 77.3% (248/321) and 72.3% (232/321). Post-vaccination 
      hepatitis A and B serologic testing were completed by 66.1% (41/62) and 61.1% 
      (11/18) of travelers, respectively. CONCLUSION: ICTs demonstrate differences in 
      travel patterns and risk. Serologic testing was uncommon, and vaccination rates 
      were low. Providers should screen ICTs early for upcoming travel plans and advise 
      vaccine completion prior to departure.
CI  - Copyright (c) 2018 Australasian College for Infection Prevention and Control. 
      Published by Elsevier B.V. All rights reserved.
FAU - Tan, Eugene M
AU  - Tan EM
AD  - Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 1st St 
      SW, Rochester, MN, 55905, USA. Electronic address: tan.eugene@mayo.edu.
FAU - Marcelin, Jasmine R
AU  - Marcelin JR
AD  - Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 1st St 
      SW, Rochester, MN, 55905, USA.
FAU - Virk, Abinash
AU  - Virk A
AD  - Division of Infectious Diseases, Department of Medicine, Mayo Clinic, 200 1st St 
      SW, Rochester, MN, 55905, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181026
PL  - Netherlands
TA  - Infect Dis Health
JT  - Infection, disease & health
JID - 101689703
RN  - 0 (Antidiarrheals)
RN  - 0 (Antimalarials)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Viral Hepatitis Vaccines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidiarrheals/administration & dosage
MH  - Antimalarials/administration & dosage
MH  - Female
MH  - HIV Infections/immunology
MH  - Hepatitis/immunology
MH  - Humans
MH  - *Immunocompromised Host
MH  - Immunosuppressive Agents/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Travel
MH  - Vaccination
MH  - Viral Hepatitis Vaccines/administration & dosage
OTO - NOTNLM
OT  - Immunization
OT  - Immunocompromised host
OT  - Vaccination
EDAT- 2018/12/14 06:00
MHDA- 2019/07/10 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/06/18 00:00 [received]
PHST- 2018/09/13 00:00 [revised]
PHST- 2018/09/17 00:00 [accepted]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
AID - S2468-0451(18)30141-X [pii]
AID - 10.1016/j.idh.2018.09.083 [doi]
PST - ppublish
SO  - Infect Dis Health. 2019 Feb;24(1):13-22. doi: 10.1016/j.idh.2018.09.083. Epub 
      2018 Oct 26.